Glenmark Pharma Receives Us Fda Approval For Generic Tecfidera Dr Capsules
Glenmark Pharmaceuticals Has Been Granted Final Approval By The United States Food &Amp; Drug Administration (Fda) For Dimethyl Fumarate Delayed-Release Capsules, 120 Mg And 240 Mg, The Generic Version Of Tecfidera Delayed-Release Capsules, 120 Mg And 240 Mg, Of Biogen.According To Iqvia Sales Data For The 12 Month Period Ending August, The Tecfidera Delayed-Release Capsules, 120 Mg And 240 Mg Market Achieved Annual Sales Of Approximately $3.8 Billion.Glenmark&Rsquo;S Current Portfolio Consists Of 164 Products Authorised For Distribution In The Us Marketplace And 46 Anda&Rsquo;S Pending Approval With The Us Fda.In Addition To These Internal Filings, Glenmark Continues To Identify And Explore External Development Partnerships To Supplement And Accelerate The Growth Of Its Existing Pipeline And Portfolio.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
